Angiotech Buys Private Firm
Shares of Angiotech Pharmaceuticals (ANPI) were getting a lift Wednesday after the drug and device maker said it agreed to acquire privately held American Medical Instruments.
The $785 million acquisition will be funded by a $600 million loan and about $200 million in cash, according to the company. The transaction is expected to close in the second quarter and should immediately add to earnings.
Angiotech's stock was up $1.44, or 11.5%, to $14.02 on heavy volume. Angiotech says the acquisition will provide it with several new product opportunities and drive long-term growth. The combined company will focus on general, plastic and ophthalmic surgery, as well as performing vascular surgery, interventional radiology and tumor biopsies.
"The acquisition of AMI significantly diversifies Angiotech's revenue base and gives the company global manufacturing, marketing and sales capabilities," the company said in a press release Wednesday.American Medical's revenue last year is estimated at $174 million, Angiotech said, representing around 46% of the combined revenue the two companies would have had in 2005 if they were already merged. For the nine-month period ended Sept. 30, Angiotech had revenue of $159.8 million. Currently, Angiotech is probably best known for providing a drug called paclitaxel that's used on Boston Scientific's (BSX) drug-coated Taxus stent. The company recently acquired drug-delivery assets from Edwards Lifesciences (EW), including a type of surgical sealant and experimental drug-eluting catheter technologies.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV